A5041489411- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Urological Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Bone health and treatments
- Urologic and reproductive health conditions
- Immune Cell Function and Interaction
- Urinary Bladder and Prostate Research
- Asthma and respiratory diseases
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- HIV Research and Treatment
- Cancer, Hypoxia, and Metabolism
- Testicular diseases and treatments
Nippon Medical School
2016-2025
Nippon Medical School Hospital
2016-2025
RIKEN Center for Advanced Intelligence Project
2024
National Hospital Organization
2006-2024
Hospital Universitario Ramón y Cajal
2024
Okayama Medical Center
1993-2024
Hôpital Saint-André
2022
Japanese Urological Association
2017-2021
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer whom the disease has progressed after chemotherapy. New treatment options are needed for patients who have not received chemotherapy, despite androgen-deprivation therapy.
The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared placebo after surgery in patients clear cell renal carcinoma at an increased risk recurrence. reported here, additional 6 months follow-up, was designed to assess longer-term efficacy and safety versus placebo, as well secondary exploratory endpoints.In multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, adults aged 18 years or older recurrence...
Abstract Deep learning algorithms have been successfully used in medical image classification. In the next stage, technology of acquiring explainable knowledge from images is highly desired. Here we show that deep algorithm enables automated acquisition features diagnostic annotation-free histopathology images. We compare prediction accuracy prostate cancer recurrence using our algorithm-generated with diagnosis by expert pathologists established criteria on 13,188 whole-mount pathology...
LBA1^ Background: Enzalutamide, an orally administered androgen receptor inhibitor, improved overall survival (OS) in men with mCRPC who had received prior docetaxel therapy (Scher et al, NEJM 367:13, 2012). This study examined whether enzalutamide could prolong OS and radiographic progression-free (rPFS) asymptomatic or mildly symptomatic chemotherapy-naive mCRPC. Methods: In this randomized, double-blind, placebo-controlled, multinational phase 3 (NCT01212991), patients were stratified by...
Abstract Background In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was prolonged use of adjuvant pembrolizumab therapy versus placebo. Patient-reported outcomes (PROs) provide an important measure health-related quality life (HRQoL) and can complement efficacy safety results. Patients Methods KEYNOTE-564, 994 were randomly assigned to receive 200 mg (n = 496) or placebo 498)...
This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated EV between January 2021 and October 2023. was administered 1.25 mg/kg on days 1, 8, 15 in a 28-day cycle. Whole-body computed tomography scans were performed to assess response. Patient characteristics, histories, response rates, progression-free survival, adverse events evaluated. Response rates determined, recorded....
Evidence has been accumulating that in many tumors, insulin-like growth factors (IGFs) promote cancer cell an autocrine/paracrine manner via the IGF-I receptor. In effort to understand role of IGFs prostate growth, we characterized IGF system components produced by human prostatic cell-lines, LNCaP, DU145, and PC-3, grown serum-free medium.IGFs, their receptors, binding proteins (IGFBPs) three lines were reverse transcriptase-polymerase chain reaction (RT-PCR), radioimmunoassay (RIA),...
Nivolumab improved overall survival (OS) and objective response rate (ORR) versus everolimus in previously treated patients with advanced renal cell carcinoma the phase III CheckMate 025 study (minimum follow-up: 14 months). We report efficacy safety global Japanese populations 26 months).Patients were randomized 1:1 to receive nivolumab 3 mg/kg intravenously every 2 weeks or 10-mg tablet orally once daily. Primary endpoint: OS, key secondary endpoints: ORR, progression-free safety.Of 410...
Nivolumab treatment resulted in superior efficacy and safety versus everolimus the 2-year follow-up of CheckMate 025 Phase III study, with consistent results global population Japanese population. Here, we report 3-year both groups. Patients were randomized 1:1 to nivolumab 3 mg/kg intravenously every 2 weeks or 10 mg orally once daily until progression/intolerable toxicity. The primary endpoint was overall survival (OS). Key secondary endpoints included objective response rate,...
Nivolumab plus ipilimumab (NIVO+IPI) demonstrated superior efficacy over sunitinib (SUN) for previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214, with a manageable safety profile. We report and extended follow-up amongst Japanese patients.CheckMate 214 patients received NIVO (3 mg/kg) IPI (1 every 3 weeks four doses, then 2 weeks; or SUN (50 mg) once daily 4 (6-week cycle). This subgroup analysis assessed overall survival (OS), objective response rate (ORR)...
Abstract Background The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in a global population. This subgroup analysis investigated the efficacy safety of pembrolizumab-axitinib patients enrolled East Asia (Japan, South Korea, Taiwan). Methods Adults with clear mRCC were randomly assigned 1:1 to receive intravenous 200 mg every...
381 Background: Although there studies have been reported that brachytherapy (BT) for prostate cancer is associated with an increased incidence of metachronous urinary bladder (MBC), few clarified differences in the clinicopathological features (CPF) MBC between BT and prostatectomy (RP). We studied risk CPF RP groups our hospital after long-term follow-up. Methods: Five hundred four patients treated 471 referred 2006 2017 were reviewed. compared including tumor number, location within...
In a previous study (Y. Koga, M. Sasaki, H. Yoshida, Wigzell, G. Kimura, and K. Nomoto, J. Immunol. 144:94-102, 1990), we demonstrated that the expression of gp160, precursor form envelope glycoprotein human immunodeficiency virus type 1, in CD4+ cells causes downregulation surface CD4 single-cell killing by forming intracellular gp160-CD4 complex. present investigated events lead to cell death expressing gp160. We found apoptosis is induced undergoing death. Moreover, even clone, which...
Abstract A plasmid which has an envelope gene from the human T lymphotropic virus IIIB isolate of HIV under transcriptional control metallothionein IIA promoter was constructed and transfected into CD4+ CD4- cell lines. When expression env induced with metal ions in cloned lines such cells, viral protein precursor, gp160, produced both clones same amounts. An extensive cytopathic effect developed resulting killing; however, this occurred only not clones. The formation syncytium found those...
Interstitial brachytherapy for localised prostate cancer may be followed by transient increases in prostate-specific antigen (PSA) that resolve without therapy. Such PSA bounces associated with an improved outcome but often cause alarm the patient and physician, have defied explanation. We developed a mathematical model to capture interactions between tumour, radiation anti-tumour immune response. The was fitted data from large cohort of patients treated exclusively interstitial...
Up to a fifth of patients diagnosed with prostate cancer (PC) will develop castration-resistant (CRPC), which has been associated poor prognosis. The aim this study was consider the patient perspective as part overall treatment decision-making process for CRPC, given that an alignment between preference and prescribing shown benefit outcomes. This examines preferences CRPC in Japan features treatments like RA-223, abiraterone, docetaxel examine extent may vary symptomatic asymptomatic...
A CD4+ human monocytoid cell line, U937, was transfected with a constructed plasmid which has the envelope gene of immunodeficiency virus under transcriptional control metallothionein IIA promoter and cloned thereafter. These lines (EH EL cells) expressed viral gp160 in cytoplasm. The expression surface CD4 antigen examined by Leu3a OKT4 monoclonal antibodies, however, disappeared completely EH cells, produce larger amount gp160, while diminishing only partly smaller gp160. results indicate...